Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Emeline M. Van Craenenbroeck et al.|The Lancet|2020Cited by 1.2k
Genetic Variants Associated With Cancer Therapy–Induced CardiomyopathyPablo García‐Pavía, Bonnie Ky, Yuri Kim et al.|Circulation|2019Cited by 346
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S. Maron, Theodore P. Abraham, Ahmad Masri et al.|New England Journal of Medicine|2024Cited by 277
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathySara Saberi, Daniel Jacoby, Nuno Cardim et al.|Circulation|2020Cited by 234
Kidney Function and Outcomes in Patients Hospitalized With Heart FailureRavi B. Patel, Muthiah Vaduganathan, Gregg C. Fonarow et al.|Journal of the American College of Cardiology|2021Cited by 196